23:37 , Jul 20, 2018 |  BioCentury  |  Finance

Earnings on deck

Earnings on deck At least 18 profitable biotechs and pharmas are slated to report earnings this week. (A) Six-month EPS figures; (B) Fiscal 1Q CompanyDatePre/post mkt2Q18 EPS est2Q17 EPSExpected chgBiogen Inc. (NASDAQ:BIIB)7/24Pre$5.24$5.044%Eli Lilly and Co. (NYSE:LLY)7/24Pre$1.30$1.1117%Gilead Sciences...
22:22 , Jul 20, 2018 |  BC Extra  |  Company News

FDA approves Pfizer's Neupogen biosimilar

FDA approved Nivestym filgrastim-aafi from Pfizer Inc. (NYSE:PFE), its biosimilar version of neutropenia drug Neupogen filgrastim from Amgen Inc. (NASDAQ:AMGN). The approval includes all indications on Neupogen's label. The approval comes two days after FDA Commissioner...
18:13 , Jul 20, 2018 |  BC Week In Review  |  Financial News

Replimune prices $100.5M IPO in middle of range

Replimune Group Inc. (NASDAQ:REPL) raised $100.5 million late July 19 through the sale of 6.7 million shares at $15 in an IPO underwritten by J.P. Morgan, Leerink and BMO Capital Markets. The price, which was...
17:33 , Jul 20, 2018 |  BC Week In Review  |  WIR Deals New Deals

Novartis in atopic dermatitis deal with MorphoSys, Galapagos

MorphoSys AG (Xetra:MOR; NASDAQ:MOR) and Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) granted Novartis AG (NYSE:NVS; SIX:NOVN) exclusive, worldwide rights to MOR106, a mAb against IL-17C that is in Phase II testing for atopic dermatitis. MorphoSys and Galapagos will...
17:11 , Jul 20, 2018 |  BC Week In Review  |  Clinical News

Amgen, UCB again seeking FDA nod for osteoporosis mAb

A year after receiving a complete response letter for Evenity romosozumab, Amgen Inc. (NASDAQ:AMGN) and UCB S.A. (Euronext:UCB) have resubmitted a BLA to FDA for the mAb to treat osteoporosis. During Evenity's initial FDA review in...
02:48 , Jul 20, 2018 |  BC Extra  |  Financial News

Replimune ticks up after pricing $100.5M IPO

Replimune Group Inc. (NASDAQ:REPL) gained $0.16 to $15.16 on Friday after it raised $100.5 million through the sale of 6.7 million shares at $15 in an IPO. Underwriters are J.P. Morgan, Leerink and BMO Capital...
22:04 , Jul 19, 2018 |  BC Innovations  |  Tools & Techniques

Immunotherapy Matchmaking

MD Anderson Cancer Center is using its access to patient samples to inject more rationality into decisions about which therapies should be paired with checkpoint inhibitors, and how to optimize the combos. The goal is...
20:37 , Jul 19, 2018 |  BC Extra  |  Company News

Novartis in atopic dermatitis deal with MorphoSys, Galapagos

MorphoSys AG (Xetra:MOR; NASDAQ:MOR) and Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) granted Novartis AG (NYSE:NVS; SIX:NOVN) exclusive, worldwide rights to MOR106, a mAb against IL-17C that is in Phase II testing for atopic dermatitis. MorphoSys and Galapagos will...
21:52 , Jul 13, 2018 |  BioCentury  |  Strategy

Roche’s partnering priority

As James Sabry gets set to lead partnering for all of Roche pharma, his first order of business might be to build out the company’s late-stage pipeline ahead of an impending patent cliff that puts...
20:22 , Jul 13, 2018 |  BC Extra  |  Company News

Amgen, UCB again seeking FDA nod for osteoporosis mAb

A year after receiving a complete response letter for Evenity romosozumab, Amgen Inc. (NASDAQ:AMGN) and UCB S.A. (Euronext:UCB) have resubmitted a BLA to FDA for the mAb to treat osteoporosis. During Evenity's initial FDA review in...